Covalon Technologies (OTCMKTS:CVALF) Posts Earnings Results, Beats Estimates By $0.06 EPS

Covalon Technologies (OTCMKTS:CVALF) announced its earnings results on Friday. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.06, Zacks reports. Covalon Technologies had a return on equity of 12.33% and a net margin of 8.58%.

Covalon Technologies Stock Performance

Shares of OTCMKTS:CVALF traded up $0.04 during midday trading on Friday, reaching $2.25. 33,532 shares of the company’s stock traded hands, compared to its average volume of 11,841. Covalon Technologies has a 1 year low of $0.74 and a 1 year high of $3.08. The company has a market cap of $61.65 million, a P/E ratio of 32.15 and a beta of -0.29. The company has a fifty day simple moving average of $2.23 and a two-hundred day simple moving average of $2.32.

Covalon Technologies Company Profile

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company’s platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.